Ascites

Zakim and Boyer's Hepatology

Volumn , Issue , 2006, Pages 333-346

  Garcia Tsao, Guadalupe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37549066550     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3258-8.50024-3     Document Type: Chapter

References (126)

1. Reuben A. My cup runneth over. Hepatology 2004, 40:503-507.
2. D'Amico G, Morabito A, Pagliaro L, Marubini E Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986, 31:468-475.
3. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004, 40:823-830.
4. Pagliaro L, D'Amico G, Pasta L, et al. Portal hypertension in cirrhosis: Natural history. Portal hypertension. Pathophysiology and treatment 1994, 72-92. Blackwell Scientific, Oxford. J. Bosch, R.J. Groszmann (Eds.).
5. Gines P, Quintero E, Arroyo V. Compensated cirrhosis: natural history and prognosis. Hepatology 1987, 7:122-128.
6. Gentilini P, Laffi G, La Villa G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 1997, 92:66-72.
7. Morali GA, Sniderman KW, Deitel KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?. J Hepatol 1992, 16:249-250.
8. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998, 114:1296-1303.
9. D'Amico G, Garcia-Tsao G, Cales P, et al. Diagnosis of portal hypertension: how and when. Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies 2001, 36-64. Blackwell Science, Oxford. R. De Franchis (Ed.).
10. Wong F, Liu P, Blendis L. Sodium homeostasis with chronic sodium loading in preascitic cirrhosis. Gut 2001, 49:847-851.
11. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis - a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8:1151-1157.
12. Gines P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998, 28:851-863.
13. Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 1998, 101:235-242.
14. Lee FY, Colombato LA, Albillos A, Groszmann RJ Nω- nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension, and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993, 17:84-90.
15. Albillos A, Lledo JL, Rossi I, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995, 109:1257-1265.
16. Schepke M, Werner E, Bieker E, et al. The angiotensin II receptor antagonist irbesartan for the treatment of portal hypertension: a placebo-controlled, double-blind study. Hepatology 2000, 32:406A.
17. Thiesson HC, Jensen BL, Jespersen B, et al. Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol 2005, 288:F1044-F1052.
18. Simel DL, Halvorsen RA, Feussner JR Quantitating bedside diagnosis: clinical evaluation of ascites. J Gen Intern Med 1988, 3:423-428.
19. Cummings S, Papadakis M, Melnick J, et al. The predictive value of physical examinations for ascites. West J Med 1985, 142:633-636.
20. Cattau EL, Benjamin SB, Knuff TE, Castell DO The accuracy of the physical examination in the diagnosis of suspected ascites. JAMA 1982, 247:1164-1166.
21. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003, 38:258-266.
22. Goldberg BB, Goodman GA, Clearfield HR Evaluation of ascites by ultrasound. Radiology 1970, 96:15-22.
23. Black M, Friedman AC Ultrasound examination in the patient with ascites. Ann Intern Med 1989, 110:253-255.
24. Runyon BA Ascites. Diseases of the liver, 7th edn. 1993, 990-1015. Lippincott Williams & Wilkins, Philadelphia. L. Schiff, E.R. Schiff (Eds.).
25. Runyon BA Management of adult patients with ascites caused by cirrhosis. Hepatology 1998, 27:264-272.
26. McVay PA, Toy PT Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991, 31:164-171.
27. Oelsner DH, Caldwell SH, Coles M, Driscoll CJ Subumbilical midline vascularity of the abdominal wall in portal hypertension observed at laparoscopy. Gastrointest Endosc 1998, 47:388-390.
28. Rector WG Spontaneous chylous ascites of cirrhosis. J Clin Gastroenterol 1984, 6:369-372.
29. Witte CL, Witte MH, Dumont AE, et al. Lymph protein in hepatic cirrhosis and experimental hepatic and portal venous hypertension. Ann Surg 1968, 168:567-577.
30. Witte CL, Witte MH The congested liver. Hepatic circulation in health and disease 1981, 307-323. Raven Press, New York. W.W. Lautt (Ed.).
31. Dumont AE, Witte CL, Witte MH Protein content of liver lymph in patients with portal hypertension secondary to hepatic cirrhosis. Lymphology 1975, 8:111-113.
32. Henriksen JH, Horn T, Christoffersen P The blood-lymph barrier in the liver. A review based on morphological and functional concepts of normal and cirrhotic liver. Liver 1984, 4:221-232.
33. Hoefs JC Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med 1983, 102:260-273.
34. Henriksen JH Colloid osmotic pressure in decompensated cirrhosis. A 'mirror image' of portal venous hypertension. Scand J Gastroenterol 1985, 20:170-174.
35. Pare P, Talbot J, Hoefs JC Serum-ascites albumin concentration gradient: a physiologic approach to the differential diagnosis of ascites. Gastroenterology 1983, 85:240-244.
36. Rector WG, Reynolds TB Superiority of the serum-ascites albumin difference over the ascites total protein concentration in separation of 'transudative' and 'exudative' ascites. Am J Med 1984, 77:83-85.
37. Albillos A, Cuervas-Mons V, Millan I, et al. Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis. Gastroenterology 1990, 98:134-140.
38. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992, 117:215-220.
39. Groszmann RJ, Wongcharatrawee S The hepatic venous pressure gradient: Anything worth doing should be done right. Hepatology 2004, 39:280-283.
40. Restuccia T, Gomez-Anson B, Guevara M, et al. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 2004, 39:1613-1622.
41. Belghiti J, Durand F. Abdominal wall hernias in the setting of cirrhosis. Semin Liver Dis 1997, 17:219-226.
42. Kirkpatrick S, Schubert T. Umbilical hernia rupture in cirrhotics with ascites. Dig Dis Sci 1988, 33:762-765.
43. Lemmer JH, Strodel WE, Eckhauser FE Umbilical hernia incarceration: a complication of medical therapy of ascites. Am J Gastroenterol 1983, 78:295-296.
44. Trotter JF, Suhocki PV Incarceration of umbilical hernia following transjugular intrahepatic portosystemic shunt for the treatment of ascites. Liver Transplant Surg 1999, 5:209-210.
45. Lieberman FL, Hidemura R, Peters RL, Reynolds TB Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites. Ann Intern Med 1966, 64:341-351.
46. Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004, 20:271-279.
47. Rubinstein D, McInnes IE, Dudley FJ Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management. Gastroenterology 1985, 88:188-191.
48. Strauss RM, Boyer TD Hepatic hydrothorax. Semin Liv Dis 1997, 17:227-232.
49. Schuster DM, Mukundan S, Small W, Fajman WA The use of the diagnostic radionuclide ascites scan to facilitate treatment decisions for hepatic hydrothorax. Clin Nucl Med 1998, 23:16-18.
50. Bhattacharya A, Mittal BR, Biswas T, et al. Radioisotope scintigraphy in the diagnosis of hepatic hydrothorax. J Gastroenterol Hepatol 2001, 16:317-321.
51. Garcia-Tsao G Spontaneous bacterial peritonitis: a historical perspective. J Hepatol 2004, 41:522-527.
52. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002, 35:140-148.
53. Evans LT, Kim WR, Poterucha JJ, Kamath PS Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003, 37:897-901.
54. Llach J, Rimola A, Navasa M, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992, 16:724-727.
55. Andreu M, Sola R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993, 104:1133-1138.
56. Xiol X, Castellvi JM, Guardiola J, et al. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology 1996, 23:719-723.
57. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000, 32:142-153.
58. Garcia-Tsao G Spontaneous bacterial peritonitis. Gastroenterol Clin North Am 1992, 21:257-275.
59. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985, 5:457-462.
60. Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. Gastroenterology 1991, 100:1737-1742.
61. Gomez-Jimenez J, Ribera E, Gasser I, et al. Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. Antimicrob Agents Chemother 1993, 37:1587-1592.
62. Rimola A, Salmeron JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995, 21:674-679.
63. Ricart E, Soriano G, Novella M, et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol 2000, 32:596-602.
64. Llovet JM, Rodriguez-Iglesias P, Moitinho E, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997, 26:88-95.
65. Fong TL, Akriviadis EA, Runyon BA, Reynolds TB Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology 1989, 9:423-426.
66. Garcia-Tsao G Spontaneous bacterial peritonitis. Clinical Gastroenterology and Hepatology 2005, 723-728. Elsevier, Philadelphia. W.M. Weinstein, C.J. Hawkey, J. Bosch (Eds.).
67. Garcia-Tsao G Further evidence against the use of aminoglycosides in cirrhotic patients. Gastroenterology 1998, 114:612-613.
68. Hampel H, Bynum GD, Zamora E, El-Serag HB Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001, 96:2206-2210.
69. Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996, 111:1011-1017.
70. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003, 38:1210-1218.
71. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.
72. Garcia-Tsao G Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 2005, 42(Suppl):S85-S92.
73. Terg R, Cobas S, Fassio E, et al. Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study. J Hepatol 2000, 33:564-569.
74. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990, 12:716-724.
75. Bauer TM, Follo A, Navasa M, et al. Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Dig Dis Sci 2002, 47:1356-1361.
76. Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999, 29:1655-1661.
77. Hou MC, Lin HC, Liu TT, et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004, 39:746-753.
78. Grange JD, Roulot D, Pelletier G, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites - a double-blind randomized trial. J Hepatol 1998, 29:430-436.
79. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997, 25:532-536.
80. Guarner C, Sola R, Soriano G, et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999, 117:414-419.
81. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996, 23:164-176.
82. Fogel MR, Sawhney VK, Neal A, et al. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol 1981, 3(Suppl 1):73-80.
83. Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983, 84:961-968.
84. Santos J, Planas R, Pardo A, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003, 39:187-192.
85. Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: Results of a randomized study. Gastroenterology 1987, 93:234-241.
86. Salerno F, Badalamenti S, Incerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients: A safe alternative therapy. J Hepatol 1987, 5:102-108.
87. Sola R, Vila MC, Andreu M, et al. Total paracentesis with dextran 40 vs. diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. J Hepatol 1994, 20:282-288.
88. Angeli P, Dalla Pria M, DeBei E, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994, 19:72-79.
89. Mirouze D, Zipser RD, Reynolds TB Effects of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 1983, 3:50-55.
90. Planas R, Arroyo V, Rimola A, et al. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983, 84:247-252.
91. Bosch-Marce M, Claria J, Titos E, et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 1999, 116:1167-1176.
92. Guevara M, Abecasis R, Terg R. Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study. Scand J Gastroenterol 2004, 39:385-386.
93. Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990, 98:146-151.
94. Fernandez-Esparrach G, Guevara M, Sort P, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997, 26:614-620.
95. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran-70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996, 111:1002-1010.
96. Ruiz del Arbol L, Monescillo A, Jimenez W, et al. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997, 113:579-586.
97. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988, 94:1493-1501.
98. Planas R, Gines P, Arroyo V, Llach J, Panes J, Vargas V, Salmeron JM, Gines A, Toledo C, Rimola A, Jimenez W, Asbert M, Gassull MA, Rodes J Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 1990, 99:1738-1744.
99. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003, 37:1147-1153.
100. Arnold C, Haag K, Blum HE, Rossle M Acute hemoperitoneum after large-volume paracentesis. Gastroenterology 1997, 113:978-982.
101. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004, 40:484-488.
102. Conn HO Sudden scrotal edema in cirrhosis: a postparacentesis syndrome. Ann Intern Med 1971, 74:943-945.
103. Ferral H, Bjarnason H, Wegryn SA, et al. Refractory ascites: early experience in treatment with transjugular intrahepatic portosystemic shunt. Radiology 1993, 189:795-801.
104. Lebrec D, Giuily N, Hadengue A, et al. and a French Group of Clinicans and a Group of Biologists. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996, 25:135-144.
105. Rossle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997, 349:1043-1049.
106. Gines P, Uriz J, Calahorra B, et al. for the International Study Group on Refractory Ascites in Cirrhosis. Transjugular intrahepatic portosystemic shunting versus repeated paracentesis plus intravenous albumin for refractory ascites in cirrhosis: A multicenter randomized comparative study. Gastroenterology 2002, 123:1839-1847.
107. Sanyal AJ, Genning C, Reddy KR, et al. and the North American Study Group for the Treatment of Refractory Ascites. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003, 124:634-641.
108. Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004, 40:629-635.
109. Garcia-Tsao G Transjugular intrahepatic portosystemic shunt for the management of refractory ascites in cirrhosis. Ascites and Renal Dysfunction in Liver Disease. 2005, 251-259. Blackwell Publishing, Oxford. 2rd edn. P. Gines, V. Arroyo, J. Rodes, R.W. Schrier (Eds.).
110. Saab S, Nieto J, Ly D, Runyon B. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2004, 3:CD004889. CD004889.
111. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004, 126:469-475.
112. Angermayr B, Cejna M, Koenig F, et al. for the Vienna TIPS Study Group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003, 38:1043-1050.
113. Boyer TD Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003, 124:1700-1710.
114. Gines P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991, 325:829-835.
115. Gines A, Planas R, Angeli P, et al. Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis. Hepatology 1995, 22:124-131.
116. Wong F, Blei AT, Blendis LM, Thuluvath PJ A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003, 37:182-191.
117. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003, 124:933-939.
118. Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol 1993, 88:514-519.
119. D'Amico G. Natural history of compensated cirrhosis and varices. Complications of cirrhosis: pathogenesis consequences and therapy 2001, 118-123. American Association for the Study of Liver Diseases, (course directors). T.D. Boyer, R.J. Groszmann (Eds.).
120. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001, 34:46-52.
121. Arroyo V, Rodes J, Gutierrez Lizarraga MA, Revert L Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976, 21:249-256.
122. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988, 94:482-487.
123. Guardiola J, Baliellas C, Xiol X, et al. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. Am J Gastroenterol 2002, 97:2374-2378.
124. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105:229-236.
125. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003, 362:1819-1827.
126. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004, 40:802-810.